Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06364228 · ClinicalTrials.gov registry record · Phase 2

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

A Phase 2 study of Stress, sponsored by University of Nebraska.

Recruiting
Registry status
Phase 2
Development phase
32
Enrollment target
1
Study location

NCT06364228 is a Phase 2 study of Stress that is actively recruiting participants, run by University of Nebraska. The registered enrollment target is 32 participants, below the 786-participant average among 152 other Stress trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06364228, a Phase 2 study of Stress, is actively recruiting participants, sponsored by University of Nebraska.

RECRUITING
Registry status
Phase 2
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

More than 15 million family caregivers provide support for individuals with Alzheimer's disease (AD) or related dementias. This number is expected to grow with the increasing population of persons with dementia (PWD). Stress in caregivers to older adults with chronic diseases is already a significant public health issue because it is associated with multiple negative physical and mental health outcomes for the caregiver (e.g., depression, cardiovascular disease) and can negatively impact the health of the PWD as well. Importantly, stress levels are even higher in female than male caregivers and in caregivers to PWD than other chronic conditions that affect older adults. There are numerous interventions to improve well-being in caregivers to PWD, but only two have been shown to moderately improve caregiver depression and quality of life in the PWD. However, both of the interventions are time and energy intensive. One promising candidate to reduce stress and improve quality of life is the endogenous neuropeptide oxytocin (OXT). Intranasal OXT interventions have been shown to successfully reduce stress and increase quality of life in other populations, including patients with borderline personality disorder, Post-traumatic Stress Disorder (PTSD), Anxiety Disorder, and Depressive Disorder. This study will assess the efficacy and safety of intranasal oxytocin (OXT) to improve the quality of life and reduce chronic stress levels in the caregivers to PWD. Participants will be randomly enrolled to one of three groups: 12 IU intranasal oxytocin, 24 IU intranasal oxytocin or placebo. The study drug will be administered daily for 21 days.

Conditions Studied

Stress

Interventions

  • DRUG Placebo
  • DRUG Oxytocin Intranasal Spray 12 International Unit (12IU)
  • DRUG Oxytocin Intranasal Spray 24 International Unit (24IU)
  • PROCEDURE Functional MRI

Study Locations (1)

Nebraska

  • University of Nebraska Medical Center, Department of Psychiatry - Omaha

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2026-01-05
Est. Completion 2027-02
Phase Phase 2

Sponsor

University of Nebraska

407 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06364228

The ClinicalTrials.gov registry entry for NCT06364228 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 152 other Stress trials with a reported enrollment target (96% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stress appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT06364228 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.

Frequently Asked Questions

What is clinical trial NCT06364228 about?

NCT06364228 is a clinical study titled "Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia". More than 15 million family caregivers provide support for individuals with Alzheimer's disease (AD) or related dementias. This number is expected to grow with the increasing population of persons with dementia (PWD). Stress in caregivers to older adults with chronic diseases is already a significan...

What is the current status of trial NCT06364228?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2026-01-05. Estimated completion is 2027-02.

What conditions does trial NCT06364228 study?

This clinical trial studies the following conditions: Stress.

What interventions are being tested in trial NCT06364228?

The interventions under investigation include: Placebo (DRUG), Oxytocin Intranasal Spray 12 International Unit (12IU) (DRUG), Oxytocin Intranasal Spray 24 International Unit (24IU) (DRUG), Functional MRI (PROCEDURE).

Who is sponsoring clinical trial NCT06364228?

This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06364228 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stress

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stress

All registered trials for this condition

Nebraska

All trials with a study site in Nebraska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.